Guardant Health, Inc. (NASDAQ: GH) Stock Competitors & Peer Comparison
See GH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GH | $154.78 | -0.37% | 20.9B | -44.35 | -$3.49 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.65% |
| TMO | $717.71 | -0.07% | 265.9B | 30.99 | $23.16 | +0.26% |
| DHR | $235.31 | -0.34% | 165.5B | 29.49 | $7.98 | +0.65% |
| IDXX | $702.59 | +0.85% | 55.4B | 49.41 | $14.22 | N/A |
| A | $176.95 | -0.52% | 49.9B | 30.45 | $5.81 | +0.57% |
| NTRA | $319.82 | +2.51% | 46.4B | -242.29 | -$1.32 | N/A |
| WAT | $470.90 | -0.97% | 46.2B | 34.41 | $13.68 | N/A |
| IQV | $274.53 | -0.23% | 45.2B | 22.63 | $12.13 | N/A |
| MTD | $1,749.01 | -0.14% | 35B | 40.19 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
GH vs DHR-PB Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GH's ROE is +2.49%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for GH.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
GH vs TMO Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, TMO has a market cap of 265.9B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while TMO trades at $717.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas TMO's P/E ratio is 30.99. In terms of profitability, GH's ROE is +2.49%, compared to TMO's ROE of +0.13%. Regarding short-term risk, GH is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for GH.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
GH vs DHR Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, DHR has a market cap of 165.5B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while DHR trades at $235.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas DHR's P/E ratio is 29.49. In terms of profitability, GH's ROE is +2.49%, compared to DHR's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for GH.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
GH vs IDXX Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, IDXX has a market cap of 55.4B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while IDXX trades at $702.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas IDXX's P/E ratio is 49.41. In terms of profitability, GH's ROE is +2.49%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, GH is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for GH.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
GH vs A Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, A has a market cap of 49.9B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while A trades at $176.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas A's P/E ratio is 30.45. In terms of profitability, GH's ROE is +2.49%, compared to A's ROE of +0.20%. Regarding short-term risk, GH is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for GH.Check A's competition here
Natera, Inc. (NASDAQ: NTRA)
GH vs NTRA Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, NTRA has a market cap of 46.4B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while NTRA trades at $319.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas NTRA's P/E ratio is -242.29. In terms of profitability, GH's ROE is +2.49%, compared to NTRA's ROE of -0.09%. Regarding short-term risk, GH is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for GH.Check NTRA's competition here
Waters Corporation (NYSE: WAT)
GH vs WAT Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, WAT has a market cap of 46.2B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while WAT trades at $470.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas WAT's P/E ratio is 34.41. In terms of profitability, GH's ROE is +2.49%, compared to WAT's ROE of +0.01%. Regarding short-term risk, GH is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for GH.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
GH vs IQV Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, IQV has a market cap of 45.2B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while IQV trades at $274.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas IQV's P/E ratio is 22.63. In terms of profitability, GH's ROE is +2.49%, compared to IQV's ROE of +0.22%. Regarding short-term risk, GH is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for GH.Check IQV's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
GH vs MTD Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, MTD has a market cap of 35B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while MTD trades at $1,749.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas MTD's P/E ratio is 40.19. In terms of profitability, GH's ROE is +2.49%, compared to MTD's ROE of +149.66%. Regarding short-term risk, GH is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for GH.Check MTD's competition here
Illumina, Inc. (NASDAQ: ILMN)
GH vs ILMN Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, ILMN has a market cap of 32.2B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while ILMN trades at $212.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas ILMN's P/E ratio is 42.33. In terms of profitability, GH's ROE is +2.49%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, GH is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for GH.Check ILMN's competition here
Labcorp Holdings Inc. (NYSE: LH)
GH vs LH Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, LH has a market cap of 30.2B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while LH trades at $372.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas LH's P/E ratio is 22.10. In terms of profitability, GH's ROE is +2.49%, compared to LH's ROE of +0.12%. Regarding short-term risk, GH is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for GH.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
GH vs DGX Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, DGX has a market cap of 28.6B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while DGX trades at $258.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas DGX's P/E ratio is 25.51. In terms of profitability, GH's ROE is +2.49%, compared to DGX's ROE of +0.15%. Regarding short-term risk, GH is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for GH.Check DGX's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
GH vs EXAS Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas EXAS's P/E ratio is -95.37. In terms of profitability, GH's ROE is +2.49%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, GH is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for GH.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
GH vs MEDP Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, MEDP has a market cap of 18.6B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while MEDP trades at $664.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas MEDP's P/E ratio is 36.85. In terms of profitability, GH's ROE is +2.49%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, GH is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for GH.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
GH vs RVTY Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, RVTY has a market cap of 17.7B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while RVTY trades at $158.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas RVTY's P/E ratio is 29.57. In terms of profitability, GH's ROE is +2.49%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, GH is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for GH.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
GH vs ILMNV Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas ILMNV's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.49%, compared to ILMNV's ROE of N/A. Regarding short-term risk, GH is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for GH.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
GH vs CRL Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, CRL has a market cap of 16.4B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while CRL trades at $342.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas CRL's P/E ratio is 34.63. In terms of profitability, GH's ROE is +2.49%, compared to CRL's ROE of +0.01%. Regarding short-term risk, GH is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for GH.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
GH vs ICLR Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, ICLR has a market cap of 15B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while ICLR trades at $199.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas ICLR's P/E ratio is 16.29. In terms of profitability, GH's ROE is +2.49%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, GH is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for GH.Check ICLR's competition here
PerkinElmer, Inc. (NYSE: PKI)
GH vs PKI Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas PKI's P/E ratio is 41.45. In terms of profitability, GH's ROE is +2.49%, compared to PKI's ROE of +0.04%. Regarding short-term risk, GH is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for GH.Check PKI's competition here
Qiagen N.V. (NYSE: QGEN)
GH vs QGEN Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while QGEN trades at $50.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas QGEN's P/E ratio is 20.79. In terms of profitability, GH's ROE is +2.49%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, GH is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for GH.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
GH vs RDNT Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while RDNT trades at $78.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas RDNT's P/E ratio is 169.70. In terms of profitability, GH's ROE is +2.49%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, GH is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for GH.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
GH vs GRAL Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, GRAL has a market cap of 5.6B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while GRAL trades at $125.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas GRAL's P/E ratio is -12.89. In terms of profitability, GH's ROE is +2.49%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, GH is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for GH.Check GRAL's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
GH vs BLLN Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, BLLN has a market cap of 5.3B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while BLLN trades at $110.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas BLLN's P/E ratio is 157.47. In terms of profitability, GH's ROE is +2.49%, compared to BLLN's ROE of +0.09%. Regarding short-term risk, GH is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for GH.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
GH vs SHC Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, SHC has a market cap of 4.7B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while SHC trades at $16.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas SHC's P/E ratio is 17.13. In terms of profitability, GH's ROE is +2.49%, compared to SHC's ROE of +0.26%. Regarding short-term risk, GH is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for GH.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
GH vs SYNH Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GH's ROE is +2.49%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for GH.Check SYNH's competition here
CareDx, Inc (NASDAQ: CDNA)
GH vs CDNA Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, CDNA has a market cap of 4.3B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while CDNA trades at $81.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas CDNA's P/E ratio is 96.63. In terms of profitability, GH's ROE is +2.49%, compared to CDNA's ROE of +0.34%. Regarding short-term risk, GH is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for GH.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
GH vs OLK Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas OLK's P/E ratio is -96.59. In terms of profitability, GH's ROE is +2.49%, compared to OLK's ROE of -0.07%. Regarding short-term risk, GH is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for GH.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
GH vs NEO Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while NEO trades at $16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas NEO's P/E ratio is 129.46. In terms of profitability, GH's ROE is +2.49%, compared to NEO's ROE of -0.04%. Regarding short-term risk, GH is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for GH.Check NEO's competition here
Veracyte, Inc. (NASDAQ: VCYT)
GH vs VCYT Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, VCYT has a market cap of 2B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while VCYT trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas VCYT's P/E ratio is 12.56. In terms of profitability, GH's ROE is +2.49%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, GH is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for GH.Check VCYT's competition here
Personalis, Inc. (NASDAQ: PSNL)
GH vs PSNL Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while PSNL trades at $15.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas PSNL's P/E ratio is -14.64. In terms of profitability, GH's ROE is +2.49%, compared to PSNL's ROE of -0.50%. Regarding short-term risk, GH is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for GH.Check PSNL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
GH vs WGS Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, WGS has a market cap of 1.6B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while WGS trades at $55.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas WGS's P/E ratio is 152.94. In terms of profitability, GH's ROE is +2.49%, compared to WGS's ROE of -0.42%. Regarding short-term risk, GH is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for GH.Check WGS's competition here
OPKO Health, Inc. (NASDAQ: OPK)
GH vs OPK Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, OPK has a market cap of 1.3B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while OPK trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas OPK's P/E ratio is -19.00. In terms of profitability, GH's ROE is +2.49%, compared to OPK's ROE of -0.12%. Regarding short-term risk, GH is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for GH.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
GH vs CSTL Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while CSTL trades at $33.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas CSTL's P/E ratio is -51.50. In terms of profitability, GH's ROE is +2.49%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, GH is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for GH.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
GH vs FLGT Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, FLGT has a market cap of 718M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while FLGT trades at $25.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas FLGT's P/E ratio is 2570.00. In terms of profitability, GH's ROE is +2.49%, compared to FLGT's ROE of -0.09%. Regarding short-term risk, GH is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for GH.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
GH vs GRALV Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas GRALV's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.49%, compared to GRALV's ROE of N/A. Regarding short-term risk, GH is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for GH.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
GH vs MYGN Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, MYGN has a market cap of 548.7M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while MYGN trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas MYGN's P/E ratio is -44.00. In terms of profitability, GH's ROE is +2.49%, compared to MYGN's ROE of -0.40%. Regarding short-term risk, GH is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for GH.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
GH vs CO Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas CO's P/E ratio is 5.06. In terms of profitability, GH's ROE is +2.49%, compared to CO's ROE of +0.11%. Regarding short-term risk, GH is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for GH.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
GH vs FLDM Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GH's ROE is +2.49%, compared to FLDM's ROE of +0.26%. Regarding short-term risk, GH is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for GH.Check FLDM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
GH vs GTH Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas GTH's P/E ratio is -1.11. In terms of profitability, GH's ROE is +2.49%, compared to GTH's ROE of -1.01%. Regarding short-term risk, GH is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for GH.Check GTH's competition here
Exagen Inc. (NASDAQ: XGN)
GH vs XGN Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, XGN has a market cap of 122M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while XGN trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas XGN's P/E ratio is -6.22. In terms of profitability, GH's ROE is +2.49%, compared to XGN's ROE of -1.26%. Regarding short-term risk, GH is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for GH.Check XGN's competition here
Genetic Technologies Limited (NASDAQ: GENE)
GH vs GENE Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas GENE's P/E ratio is -38.25. In terms of profitability, GH's ROE is +2.49%, compared to GENE's ROE of -1.85%. Regarding short-term risk, GH is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for GH.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
GH vs FRNM Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, FRNM has a market cap of 94.3M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while FRNM trades at $11.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas FRNM's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.49%, compared to FRNM's ROE of N/A. Regarding short-term risk, GH is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for GH.Check FRNM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
GH vs BDSX Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, BDSX has a market cap of 82.4M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while BDSX trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas BDSX's P/E ratio is -3.19. In terms of profitability, GH's ROE is +2.49%, compared to BDSX's ROE of -4.42%. Regarding short-term risk, GH is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for GH.Check BDSX's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
GH vs IMDX Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, IMDX has a market cap of 78.2M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while IMDX trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas IMDX's P/E ratio is -1.60. In terms of profitability, GH's ROE is +2.49%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, GH is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for GH.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
GH vs PRPO Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, PRPO has a market cap of 44.4M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while PRPO trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas PRPO's P/E ratio is -38.15. In terms of profitability, GH's ROE is +2.49%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, GH is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for GH.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
GH vs AKU Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas AKU's P/E ratio is -0.13. In terms of profitability, GH's ROE is +2.49%, compared to AKU's ROE of -5.32%. Regarding short-term risk, GH is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for GH.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
GH vs CEMI Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GH's ROE is +2.49%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GH is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for GH.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
GH vs ENZ Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GH's ROE is +2.49%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, GH is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for GH.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
GH vs PMD Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas PMD's P/E ratio is -5.24. In terms of profitability, GH's ROE is +2.49%, compared to PMD's ROE of -0.32%. Regarding short-term risk, GH is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for GH.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
GH vs ME Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas ME's P/E ratio is -0.03. In terms of profitability, GH's ROE is +2.49%, compared to ME's ROE of -3.47%. Regarding short-term risk, GH is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for GH.Check ME's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
GH vs BIAF Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, BIAF has a market cap of 15.2M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while BIAF trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas BIAF's P/E ratio is -0.28. In terms of profitability, GH's ROE is +2.49%, compared to BIAF's ROE of -3.31%. Regarding short-term risk, GH is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for GH.Check BIAF's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
GH vs MYNZ Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, GH's ROE is +2.49%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, GH is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for GH.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
GH vs BNR Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, BNR has a market cap of 14.3M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while BNR trades at $13.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas BNR's P/E ratio is -15.57. In terms of profitability, GH's ROE is +2.49%, compared to BNR's ROE of -0.13%. Regarding short-term risk, GH is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for GH.Check BNR's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
GH vs QUCY Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, QUCY has a market cap of 14.2M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while QUCY trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas QUCY's P/E ratio is -0.03. In terms of profitability, GH's ROE is +2.49%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, GH is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for GH.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
GH vs MDXH Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, MDXH has a market cap of 14M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while MDXH trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas MDXH's P/E ratio is -0.20. In terms of profitability, GH's ROE is +2.49%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, GH is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for GH.Check MDXH's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
GH vs CHEK Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas CHEK's P/E ratio is -0.43. In terms of profitability, GH's ROE is +2.49%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, GH is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for GH.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
GH vs CNTG Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GH's ROE is +2.49%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GH is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for GH.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
GH vs APDN Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas APDN's P/E ratio is -0.10. In terms of profitability, GH's ROE is +2.49%, compared to APDN's ROE of -5.84%. Regarding short-term risk, GH is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for GH.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
GH vs NDRA Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while NDRA trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas NDRA's P/E ratio is -0.70. In terms of profitability, GH's ROE is +2.49%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, GH is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for GH.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
GH vs BIAFW Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, BIAFW has a market cap of 5.9M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while BIAFW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas BIAFW's P/E ratio is 0.62. In terms of profitability, GH's ROE is +2.49%, compared to BIAFW's ROE of -3.31%. Regarding short-term risk, GH is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for GH.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
GH vs NVTA Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GH's ROE is +2.49%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GH is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for GH.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
GH vs LMDXW Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GH's ROE is +2.49%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for GH.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
GH vs LMDX Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GH's ROE is +2.49%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for GH.Check LMDX's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
GH vs ADVB Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, ADVB has a market cap of 3.8M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while ADVB trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas ADVB's P/E ratio is -21.09. In terms of profitability, GH's ROE is +2.49%, compared to ADVB's ROE of +0.79%. Regarding short-term risk, GH is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for GH.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
GH vs DMTK Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GH's ROE is +2.49%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, GH is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for GH.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
GH vs NOTV Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas NOTV's P/E ratio is -0.03. In terms of profitability, GH's ROE is +2.49%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, GH is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for GH.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
GH vs SQL Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas SQL's P/E ratio is -0.40. In terms of profitability, GH's ROE is +2.49%, compared to SQL's ROE of -30.46%. Regarding short-term risk, GH is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for GH.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
GH vs AWH Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas AWH's P/E ratio is -0.09. In terms of profitability, GH's ROE is +2.49%, compared to AWH's ROE of +1.62%. Regarding short-term risk, GH is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for GH.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
GH vs ISPC Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, ISPC has a market cap of 1.8M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while ISPC trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas ISPC's P/E ratio is -0.02. In terms of profitability, GH's ROE is +2.49%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, GH is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for GH.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
GH vs HTGM Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GH's ROE is +2.49%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GH is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for GH.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
GH vs BIOC Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GH's ROE is +2.49%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GH is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for GH.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
GH vs SQLLW Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, GH's ROE is +2.49%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, GH is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for GH.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
GH vs WGSWW Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, GH's ROE is +2.49%, compared to WGSWW's ROE of -0.42%. Regarding short-term risk, GH is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for GH.Check WGSWW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
GH vs PRXL Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas PRXL's P/E ratio is 42.97. In terms of profitability, GH's ROE is +2.49%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, GH is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for GH.Check PRXL's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
GH vs CHEKZ Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.49%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, GH is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for GH.Check CHEKZ's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
GH vs BNGOW Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas BNGOW's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.49%, compared to BNGOW's ROE of -0.85%. Regarding short-term risk, GH is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for GH.Check BNGOW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
GH vs OCDX Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GH's ROE is +2.49%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GH is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for GH.Check OCDX's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
GH vs MEUSW Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.49%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, GH is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for GH.Check MEUSW's competition here
Danaher Corporation (NYSE: DHR-PA)
GH vs DHR-PA Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GH's ROE is +2.49%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for GH.Check DHR-PA's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
GH vs NDRAW Comparison November 2026
Guardant Health, Inc. (NASDAQ: GH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 20.9B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, GH is priced at $154.78 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -44.35, whereas NDRAW's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.49%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, GH is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for GH.Check NDRAW's competition here